Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers target price on Tate & Lyle

(Sharecast News) - Analysts at Berenberg lowered their target price on food ingredients manufacturer Tate & Lyle from 890.0p to 860.0p on Monday due to FX headwinds. Berenberg noted that Tate & Lyle had reported its third-quarter trading update on 21 February, with sales guidance for the year being reduced to "slightly below" FY23 levels due to lower pricing as a result of lower raw material costs and its pass-through pricing policy.

Meanwhile, adjusted underlying earnings guidance for 7-9% growth in constant currency remained unchanged. However, Berenberg said it had still opted to downgrade its FY24 earnings per share estimates by 3% as a result of currency exchange headwinds.

"In FY 2023, Tate implemented supplementary pricing in FBS to cover sharp input cost inflation, driven by the conflict in Ukraine. The bulk of the impact from this began in Q3 FY 2023, leading to a drop off in reported pricing in Q3 FY 2024. Price/mix moderated to 8% in Q3 FY 2024, following 16.6% in H1," said Berenberg. "This 8% growth was split equally between inflation-driven pricing and the more standard price/mix reported during less-volatile periods for input costs."

Looking ahead, the German bank noted that the balance of Tate's organic growth between volume and mix will depend on how the consumer environment improves throughout the year, stating that so far in Q4, volume momentum had been positive, and that management expects this to continue throughout FY25.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Oxford Biomedica confident as it moves away from vaccine era
(Sharecast News) - Cell and gene therapy contract development and manufacturing organisation (CDMO) Oxford Biomedica reported stability in its core business on Monday, with a small increase in full-year core revenue for 2023, despite a 36% decrease in total revenue to £89.5m.
N Brown chairman Ron McMillan to retire
(Sharecast News) - N Brown said on Monday that chairman Ron McMillan will be retiring and stepping down from the board with effect from 30 April for personal reasons.
McCarthy out, Adshead in as Ultimate Products chair
(Sharecast News) - Ultimate Products, the parent of homeware brands including Salter and Beldray, announced a change in its leadership on Monday, with James 'Jim' McCarthy deciding to step down as non-executive chair from 31 July.
Supermarket Income REIT buys portfolio of Carrefour supermarkets for €75.3m
(Sharecast News) - Supermarket Income REIT said on Monday that it has bought a portfolio of Carrefour supermarkets in France through a sale and leaseback transaction for €75.3m.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.